| Eugene Conte, DO | |
|
8940 Kingsridge Dr, Ste 104, Centerville, OH 45458-1632 | |
| (937) 436-1433 | |
| (937) 439-7443 |
| Full Name | Eugene Conte |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 46 Years |
| Location | 8940 Kingsridge Dr, Centerville, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316056567 | NPI | - | NPPES |
| 0523482 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 34003451 (Ohio) | Primary |
| 207N00000X | Dermatology | 1889 (Arizona) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| David B Roy Do Pa | 2365767118 | 11 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.
Beneficiaries are encouraged to take a close look at their options during their upcoming enrollment period, which is separate from the sign-up in the health law's marketplaces.
A $10.2 million commitment from the Robertson Foundation to create a state-of-the-art Translational Cell Therapy Center (TCTC) will advance Duke Medicine's pioneering cell therapy research and treatment programs for children and adults with cancer, cerebral palsy, stroke and brain injuries suffered at birth.
How the gene that has been pegged as a major risk factor for schizophrenia and other mood disorders that affect millions of Americans contributes to these diseases remains unclear.
› Verified 6 days ago
| Entity Name | David B Roy Do Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194124834 PECOS PAC ID: 2365767118 Enrollment ID: O20150219000500 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.
Beneficiaries are encouraged to take a close look at their options during their upcoming enrollment period, which is separate from the sign-up in the health law's marketplaces.
A $10.2 million commitment from the Robertson Foundation to create a state-of-the-art Translational Cell Therapy Center (TCTC) will advance Duke Medicine's pioneering cell therapy research and treatment programs for children and adults with cancer, cerebral palsy, stroke and brain injuries suffered at birth.
How the gene that has been pegged as a major risk factor for schizophrenia and other mood disorders that affect millions of Americans contributes to these diseases remains unclear.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eugene Conte, DO 151 Southhall Ln, Ste 300, Maitland, FL 32751-7176 Ph: (407) 875-2080 | Eugene Conte, DO 8940 Kingsridge Dr, Ste 104, Centerville, OH 45458-1632 Ph: (937) 436-1433 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.
Beneficiaries are encouraged to take a close look at their options during their upcoming enrollment period, which is separate from the sign-up in the health law's marketplaces.
A $10.2 million commitment from the Robertson Foundation to create a state-of-the-art Translational Cell Therapy Center (TCTC) will advance Duke Medicine's pioneering cell therapy research and treatment programs for children and adults with cancer, cerebral palsy, stroke and brain injuries suffered at birth.
How the gene that has been pegged as a major risk factor for schizophrenia and other mood disorders that affect millions of Americans contributes to these diseases remains unclear.
› Verified 6 days ago
Dr. Barbara Baughman Cortez, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 273 Regency Ridge Dr, Centerville, OH 45459 Phone: 937-433-2130 Fax: 937-433-2157 | |
Dr. Gary D Palmer, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6720 Loop Rd, Centerville, OH 45459 Phone: 937-433-4922 Fax: 937-433-6520 | |
Patricia A Dickerson, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1299 E Alex Bell Rd, Centerville, OH 45459 Phone: 937-436-1117 Fax: 937-436-9576 | |
Dr. Karl K Kellawan Ii, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 220 E Spring Valley Pike, Centerville, OH 45458 Phone: 937-438-3376 Fax: 937-438-9424 | |
William Harry Abildgaard Jr., MD Dermatology Medicare: Medicare Enrolled Practice Location: 400 N Main St Ste D, Centerville, OH 45459 Phone: 937-438-3376 Fax: 937-438-9424 |